For more information regarding these studies, contact Cancer Research & Registry at (601) 984-1095
E3A06: Randomized Phase III Trial of Lenalidomide versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma
Asymptomatic high-risk myeloma is a type of blood cell cancer that has not yet damaged body tissue and organs to the point where symptoms are noticeable. The current accepted treatment for asymptomatic high-risk myeloma is to receive no therapy.
This study is being done to find out what effects, good or bad, an experimental drug, called lenalidomide, has on you and on your asymptomatic high-risk multiple myeloma and to compare this with participants that receive no therapy. Lenalidomide is a drug that has shown benefit and is approved for use in people whose myeloma has been resistant to other therapies. The mechanism by which lenalidomide works in myeloma is still unclear, but it is felt that the drug works by making the immune system (your body's natural defense against disease) work better against the myeloma cells. It may also have additional direct effects on the myeloma cells. This drug is approved for symptomatic myeloma and myelodysplastic syndrome (disease of blood and bone) and other uses but not for treatment of asymptomatic high-risk smoldering multiple myeloma, which makes its use in this study experimental.
Principal Investigator: Stephanie Elkins, MD
DF 10-106: A Randomized, Phase III Study Comparing Conventional Dose Treatment Using A Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 years of age
This study is being done for newly diagnosed multiple myeloma.
The purpose of this study is to look at the drug combination of lenalidomide, bortezomib and dexamethasone compared to the drugs with autologous stem cell transplantation to see side effects and how well it works for treatment of newly diagnosed multiple myeloma.
The drugs, lenalidomide, bortezomib, and dexamethasone, are approved by the U.S. Food and Drug Administration (FDA), but they have not been approved in this combination for use in any type of cancer. These drugs have been used in other research studies in patients with multiple myeloma and information from those other research studies suggests that this combination of therapy may help to treat newly diagnosed multiple myeloma.
Principal Investigator: Carter Milner, MD
S1211: A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide with or without Elotuzumab (NSC-764479) for newly diagnosed high risk multiple myeloma (HRMM)
The usual treatment for multiple myeloma is the combination of bortezomib, lenalidomide, and dexamethasone (RVD). The purpose of this study is to try to find out what effects, good and/or bad, adding elotuzumab to RVD therapy has on treatment for myeloma. Elotuzumab is an experimental drug that is currently being tested in cancer patients. There are laboratory results that suggest that RVD might work better if elotuzumab is added.
No trials for Refractory/Relapsed Sarcoma are being conducted at UMMC/UMHC.
2500 North State Street
Jackson, MS 39216
General Information: 601-984-1000
Patient Appointments: 888-815-2005